Is TARA or TBPH more undervalued in 2026?

CirclFi compares Protara Therapeutics, Inc. (TARA) and Theravance Biopharma, Inc. (TBPH) using 13 institutional-grade valuation models. TARA has a Quality of Company score of 4.1/10 while TBPH scores 8.4/10.

Which is a better buy — TARA or TBPH?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do TARA and TBPH valuations compare?

TARA at $4.75 and TBPH at $16.21 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

TARA vs TBPH Valuation Comparison 2026 — Intrinsic Value Analysis

TARA

Biotechnology

Protara Therapeutics, Inc.

Quality

4.1

out of 10

Value Trap

LOW

Price

$4.75

Last close

Models

7/13

Active

TBPH

Biotechnology

Theravance Biopharma, Inc.

Quality

8.4

out of 10

Value Trap

SAFE

Price

$16.21

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	TARA Fair Value	TARA Upside	TBPH Fair Value	TBPH Upside
Bayesian DCF	Intrinsic	$1.39	-70.6%	—	—
Earnings Power Value	Intrinsic	—	—	$10.88	-35.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$7.39	+49.0%	$4.67	-71.2%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.67	-43.8%	$10.68	-34.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for TARA vs TBPH — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TARA vs TBPH — Which Stock Is More Undervalued?

TBPH scores higher with a 8.4/10 quality rating vs TARA's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Protara Therapeutics, Inc. (TARA) and Theravance Biopharma, Inc. (TBPH) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TARA currently trades at $4.75 with a QOC of 4.1/10, while TBPH trades at $16.21 with a QOC of 8.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).